BLOOD TESTING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Blood Testing Market Size and Forecast – 2025 to 2032

The global blood testing market is estimated to be valued at USD 106.10 Bn in 2025 and is expected to reach USD 192.71 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 8.9% from 2025 to 2032. This substantial growth is driven by the increasing prevalence of chronic diseases, technological advancements in diagnostic tools, and rising demand for personalized medicine. Enhanced healthcare infrastructure and expanding geriatric population further contribute to the market’s robust expansion over the forecast period.

Key Takeaways of the Global Blood Testing Market

• By test type, the clinical chemistry segment is expected to account for the largest share of the global blood testing market at 35.3% in 2025.
• By technology, the immunoassay segment is expected to lead the market with 23.4% share in 2025.
• By product, the reagents and kits segment is projected to dominate the market, representing 45.3% of the market share in 2025.
• North America is expected to lead the market, holding a share of 40.3% in 2025. Asia Pacific is anticipated to be the fastest-growing region, with a market share of 24.3% in 2025.

Market Overview

Current market trends highlight a growing emphasis on point-of-care testing and home-based blood testing kits, which provide faster and more convenient diagnostic solutions. Integration of artificial intelligence and IoT in blood testing technologies is enhancing accuracy and real-time data analysis. Additionally, the shift towards minimally invasive testing methods and increasing adoption of liquid biopsy for cancer detection illustrate the market’s innovation trajectory. These trends collectively amplify the market’s potential, supporting better patient outcomes and increasing healthcare efficiency globally.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Blood Testing Market Insights, by Test Type - Clinical Chemistry Segment Dominance Driven by Broad Diagnostic Applications and Technological Advancements

By test type, the clinical chemistry segment is projected to account for 35.3% share in 2025, due to the vast application scope and the necessity of routine diagnostics. Clinical chemistry tests identify the chemical components in blood which give important information on the metabolic functions, organ health and electrolyte balance. They are used as the basis of diagnosing diseases like diabetes, heart diseases, liver diseases and kidney diseases that are among the most common health disorders in the world.

In December 2023, Lupin Diagnostics, the diagnostics arm of pharmaceutical major Lupin, opened a new regional reference laboratory in Chennai, Tamil Nadu, expanding its network to 36 labs and over 600 collection centers across India. Equipped with advanced technologies and clinical expertise, the facility strengthens Lupin’s blood testing and diagnostic services, with plans to add more than 300 collection centers in South India and 50 in Tamil Nadu by FY25.

Blood Testing Market Insights, by Technology - Immunoassay Segment Leading Through Sensitivity and Diverse Clinical Utility

The immunoassay segment is expected to capture 23.4% share in 2025, because of its high sensitivity and specificity in that it has a wide range of biomarkers. The immunoassay technology is based on the antigen-antibody reactions, which can be used to accurately determine the quantity of proteins, hormones, and other molecules in blood. It is essential to use it in applications, including infectious disease diagnosis (including HIV, Hepatitis, and emerging viral illnesses such as COVID-19), monitoring autoimmune disorders, cancer biomarker and allergy testing.

In March 2024, Sysmex Corporation, a Japan-based global leader in clinical laboratory testing and diagnostics, began sales of six new immunoassay kits under its HISCL Series for gynecological and gonadal hormone testing, including assays for LH, FSH, prolactin, estradiol, progesterone, and testosterone.

Blood Testing Market Insights, by Product - Reagents and Kits are Dominating Due to High Consumption in Routine Diagnostics and Research

The reagents and kits segment is projected to hold 45.3% share in 2025, due to their essential role in the execution of virtually all types and technologies of blood tests. Reagent kits and reagents contain crucial chemicals, enzymes, antibodies and substrates needed to perform accurate diagnostic tests, thus they are indispensable in both laboratories and point of care testing centers.

It is due to the growing number and variety of blood tests around the world that fuels the continuous demand of high-quality, standardized reagents. With the trend towards increasingly complex diagnostic workflows based on personalized medicine and multiplex testing, reagent kits have developed to provide less-custodial, conveniently-prepared formats and save preparation and time and reduce variability.

Regional Insights

To learn more about this report, Download Free Sample

North America Blood Testing Market Analysis and Trends

The blood testing market in North America continues to dominate with an estimated 40.3% share in 2025, heavy investments in research and development, and established ecosystem that encourages innovations. The market is reinforced by the presence of the large companies in the industry, like Thermo Fisher Scientific, Becton Dickson, and Abbott Laboratories, which constantly present the new high-tech diagnostic technologies. Favorable policies by the U.S. FDA and substantial investments in healthcare programs have also boosted the rate of adoption, through the provision of favorable policies by the government.

In October 2024, Terumo Blood and Cell Technologies, a global leader in blood management solutions, launched its Reveos Automated Blood Processing System in the United States to improve efficiency in blood testing and component separation. The system, already used in over 50 countries, automates the processing of whole blood into platelets, plasma, and red cells in a single cycle, cutting manual steps by up to 65%.

Asia Pacific Blood Testing Market Analysis and Trends

Asia Pacific region is experiencing the most rapidly growing blood testing market due to the growing healthcare infrastructure with an estimated share of 24.3% in 2025, growing awareness of preventative diagnostics, and growing prevalence of chronic diseases. The urbanization of countries such as China and India and the government spending on healthcare modernization is driving the market growth. The market ecosystem involves the presence of both new local firms and international corporations such as Roche and Siemens Healthineers that work together using joint ventures and partnerships. The Asia Pacific is also becoming a dynamic growth centre by facilitating market entry and scale-up plans because trade liberalization and better regulatory environments allow these strategies.

Blood Testing Market Outlook for Key Countries

U.S. Blood Testing Market Analysis and Trends

The U.S. is a key market in blood testing because of its high level of biotechnology and the existence of the strongest blood testing companies like Quest Diagnostics and Bio-Rad Laboratories. Innovation in molecular diagnostics and point-of-care testing platforms is also being carried out continuously in the U.S. blood testing market. Moreover, the participation of government in enhancing early detection of diseases and personalized medicine also plays a major role in growing the market. The healthcare coverage and the large accessibility to diagnostic services in the country helps in strengthening its supremacy on the market.

On September 09, 2025, Telomir Pharmaceuticals, a U.S.-based preclinical-stage biotechnology company developing therapies for aging and cancer, announced new preclinical data showing its candidate Telomir-1 reset DNA methylation to reactivate the CDKN2A tumor suppressor gene in aggressive prostate cancer cells.

China Blood Testing Market Analysis and Trends

The blood testing market in China has been changing very fast and this is supported by high government efforts to improve the primary healthcare services and increase the coverage of diagnostic test. Strong local firms such as Mindray medical international and international firms such as Becton Dickson are contributing to market development actively by launching products that are localized to local requirements. Furthermore, the regulatory restructuring in China that has enabled faster approvals has promoted innovation and foreign capital that has enabled market to react effectively to the increasing demands.

In April 2024, Grifols, a Spain-based global leader in plasma-derived medicines and diagnostic solutions, launched its fully automated Erytra Eflexis blood-typing system in China after regulatory approval. The system, designed to improve pretransfusion compatibility testing using Grifols’ DG gel technology, enhances efficiency and accuracy in hospital laboratories.

Germany Blood Testing Market Analysis and Trends

Germany is still a leader of the Europe blood testing market with a highly developed healthcare system and high quality standards. Large medical technology companies such as Siemens Healthineers and Roche Diagnostics have operations in Germany that are significant, which leads to the positive development of automated and high-throughput blood tests solutions. The focus of precision medicine in the country, together with the consistent government funding of innovations in the healthcare industry, keeps the country in the center of the market ecosystem in the region.

In February 2025, hema.to, a Munich-based digital medtech startup specializing in AI-powered blood data analysis, secured USD 3.9 million in funding led by LUMO Labs with participation from Bayern Kapital and U.S. angel investors. The company’s platform automates complex cytometry for blood testing, reducing analysis time from 20 minutes to 1 minute, eliminating subjectivity, and cutting false negatives in detecting leukemia and lymphoma by 90%.

India Blood Testing Market Analysis and Trends

The blood testing market in India can be characterized by the high growth rate due to the increasing healthcare accessibility and the increasing prevalence of lifestyle-related disorders that need regular blood testing. The availability of diagnostic services is improved through government initiatives on rural health infrastructure and an increase in the number of public-private partnerships. Firms such as Transasia Bio-Medicals and the international giants such as Abbott are increasing their distribution channels and introducing low-cost diagnostic solutions to satisfy the economically-sensitive groups, and this has increased market penetration.

In June 2025, Amazon India, the e-commerce giant expanding into healthcare through Amazon Medical, launched Amazon Diagnostics, an at-home blood testing and diagnostics service across Bengaluru, Delhi, Gurgaon, Noida, Mumbai, and Hyderabad.

End User Feedback and Unmet Needs - Blood Testing Market

• The convenience and efficiency of the contemporary blood testing solutions are repeatedly emphasized by the end users in hospitals, diagnostic laboratories, and government healthcare systems, especially with the increase of point-of-care and at-home testing models. Most laboratories testify that automation and digital integration has considerably cut down turnaround time and it is more likely to provide timely results to the case of critical care. Good evidence is provided by the healthcare providers in urban networks who hail the use of advanced immunoassay platforms because of their capability to handle large quantities of samples with the same degree of accuracy, facilitating an easier working process and improved patient results. Such feedback demonstrates the increased level of appreciation of technologies that are both reliable and fast because they directly affect clinical decision-making and patient satisfaction.
• Meanwhile, there have been issues of accessibility and affordability, particularly in low-resource environments where expensive systems are either not affordable or not available. The challenge of using molecular blood testing in rural areas (because of expensive equipment prices, insufficiently trained personnel, and weak connectivity to implement digital reporting) is mentioned as a recurring problem by government health initiatives. These gaps also point to unmet needs like cheaper testing kits, easier-to-use user interfaces, and decentralized healthcare system-adaptable solutions. The opportunity to deal with these difficulties might open major prospects of manufacturers to enter the virgin market, enhance user loyalty over the long run, and drive innovations that would balance between high-technology and practicality. Investing in low cost and scalable testing systems will empower the health systems of the people and guarantee wider inclusion in preventive care services among the policymakers.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Download Free Sample

Key Developments

• On September 10, 2025, Exact Sciences, a U.S.-based leader in cancer diagnostics, launched Cancerguard, the first commercially available multi-cancer early detection blood test that analyzes multiple biomarker classes to identify signals from over 50 cancer types, including high-mortality cancers such as pancreatic, ovarian, liver, lung, and stomach.
• In August 2025, Labcorp, a global leader in laboratory services, launched the Lumipulse pTau-217/Beta Amyloid 42 Ratio, the first U.S. FDA-cleared blood testing method for Alzheimer’s disease, developed by Fujirebio Diagnostics. Now available nationwide through Labcorp, the test enables early detection of amyloid plaques from a simple blood draw, offering a less invasive and more accessible alternative to lumbar punctures and PET scans, with clinical studies showing predictive values above 90%.
• In May 2025, Fujirebio, a global diagnostics company specializing in innovative in-vitro testing solutions, received U.S. FDA clearance for the first blood testing method to aid in diagnosing Alzheimer’s disease
• In May 2025, Haemanthus, a new startup founded by Billy Evans, partner of jailed Theranos founder Elizabeth Holmes, emerged claiming a “radically new approach” to diagnostics with a machine that uses lasers to analyze blood, saliva, and urine for detecting cancers and infections. The company, which resembles Theranos in concept and even in the design of its device, is seeking to raise over USD 50 million and plans to begin with pet health before moving to human testing, with Holmes reportedly advising Evans despite serving her prison sentence.

Top Strategies Followed by Global Blood Testing Market Players

• Established industry giants dominate the landscape through substantial investments in research and development (R&D), aiming to innovate and launch high-performance, reliable blood testing products that meet the evolving demands of healthcare providers and patients. Their R&D efforts often lead to breakthroughs in areas such as rapid diagnostics, improved sensitivity, and integration with digital health platforms.
  • In December 2024, BD, one of the world’s largest medical technology companies, and Babson Diagnostics, a U.S.-based health care technology firm, announced the expansion of their fingertip blood testing solution for health systems and provider networks across the United States. The collaboration integrates BD’s MiniDraw capillary blood collection system with Babson’s BetterWay technology, enabling accurate results from just six drops of blood collected from a fingertip.

• Mid-level players in the blood testing market adopt a somewhat different approach, focusing primarily on delivering cost-effective solutions that strike a crucial balance between quality and affordability. Recognizing the sensitivity of price-conscious consumers, these companies design products and assays that maintain reliable performance while remaining accessible to a broader patient base, especially in developing regions.
  • Instances of companies focusing on cost-effective, accessible solutions include Ortho Clinical Diagnostics, which offers reliable but affordable immunoassay and clinical chemistry systems widely used in developing regions; DiaSorin S.p.A., known for its cost-sensitive diagnostic kits targeting infectious diseases; and Nova Biomedical, which delivers point-of-care blood testing devices with emphasis on affordability and usability in resource-limited settings.

• Small-scale players, despite limited resources, compete by carving specialized niches within the global blood testing market. They often differentiate themselves by focusing on unique product features, such as portable point-of-care devices, tailored assay kits for rare biomarkers, or rapid turnaround times that address unmet needs in specific healthcare settings. Embracing cutting-edge technologies like microfluidics, artificial intelligence, and biosensors allows these companies to maintain competitiveness and appeal to particular customer segments seeking innovation.
  • Examples of smaller, niche-focused innovators include Trivitron Healthcare from India, developing portable and affordable diagnostic kits tailored for local healthcare settings; Randox Laboratories, which has introduced specialized biomarker assays and microfluidics-based diagnostics; and hema.to, a German medtech startup leveraging AI-based cytometry for blood cancer detection. Other startups like Epitope Diagnostics focus on rapid testing kits for specific biomarkers.

Market Report Scope

Blood Testing Market Report Coverage

Blood Testing Market Dynamics

To learn more about this report, Download Free Sample

Blood Testing Market Driver - Rising Prevalence of Chronic and Infectious Diseases

Rising trend of chronic diseases like diabetes, cardiovascular diseases, and cancer, and the unremitting impact of infectious diseases like HIV, hepatitis, and tuberculosis are among the key drivers of blood test demand across the world. Such conditions must be monitored regularly and diagnosed early, and blood testing becomes a very valuable instrument in the management of the disease and timely intervention. Medical technology has also improved the precision and effectiveness of blood tests and this has further promoted their widespread use by health professionals. Also, the increased awareness on preventive healthcare has seen more people choose to undergo regular blood screening as an easy method of establishing early abnormalities in relation to chronic and infectious conditions.

 In December 2024, WHO reported that non-communicable diseases caused at least 43 million deaths in 2021, accounting for 75% of global non-pandemic deaths, with 18 million people dying before age 70 and most of these premature deaths occurring in low- and middle-income countries. Cardiovascular diseases led with 19 million deaths, followed by cancers at 10 million, chronic respiratory diseases at 4 million, and diabetes over 2 million. WHO noted that tobacco use, unhealthy diets, physical inactivity, alcohol misuse and air pollution are the main drivers, while raised blood pressure, obesity and high glucose levels are leading metabolic risks, with air pollution alone linked to 5.6 million noncommunicable disease deaths.

Blood Testing Market Opportunity - Integration of AI and Digital Health in Diagnostics

The adoption of Artificial Intelligence (AI) and digital health technologies is a major prospect in the worldwide blood testing industry as it is transforming the accuracy, efficiency, and accessibility of the diagnostic process. The input complexity of a blood test can be analyzed at a speed of a few seconds to provide early disease detection and custom treatment plans, even with the help of AI-powered algorithms. This technological breakthrough can result in reduced human error and faster turnaround times of results, which can positively influence patient outcomes and clinical workflow optimization. Moreover, the use of digital health platforms will bring about the seamless exchange of data among laboratories, healthcare providers, and patients, which encourages real-time monitoring and remote diagnostics.

In July 2025, Forte, a Sri Lanka-based healthcare company, together with Health Vectors, a digital health solutions provider, launched the country’s first AI-powered diagnostic platform that includes blood testing and other health assessments. The collaboration aims to democratize healthcare by integrating artificial intelligence into diagnostics, enabling faster, more accurate reporting and giving patients easier access to critical health information.

Analyst Opinion (Expert Opinion)

• The global blood testing market is being shaped by several strong forces. Technological advancements such as next-generation sequencing, molecular diagnostics, and AI-enabled testing tools are improving accuracy and speed, while regulatory support for early disease detection has further accelerated adoption. Rising prevalence of chronic and infectious diseases continues to drive demand, and new opportunities are opening through the expansion of point-of-care testing, personalized medicine, and digital health integration. At the same time, the industry faces hurdles including high costs of advanced tests, disparities in access across developing regions, and the need to overcome concerns around false results and standardization. Industry platforms like MEDICA in Germany, the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting, and WorldLab-EuroMedLab have in recent years served as vital stages for knowledge-sharing and technology showcase, helping shape policies and highlight innovative diagnostic solutions.
• Recent developments illustrate the market’s transformation. Exact Sciences launched Cancerguard, a multi-cancer early detection blood test, while Labcorp introduced the first U.S. FDA-cleared blood test for Alzheimer’s disease, both marking milestones in expanding blood-based diagnostics. Amazon Diagnostics in India, developed with Orange Health Labs, has created new models for accessible at-home testing, and Quick Vitals’ AI-powered non-invasive tool deployed at Niloufer Hospital in Hyderabad shows the potential of digital diagnostics in public healthcare. National initiatives such as the U.S. Cancer Moonshot program and EU-backed investments in precision medicine are reinforcing the role of blood testing in preventive care and population health, ensuring the market remains central to the future of global healthcare delivery.

Market Segmentation

• Test Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Clinical Chemistry
    • Basic/Lipid Metabolic Panels
    • Electrolyte Panel
    • Liver Function Tests
    • Renal Function Tests
    • Thyroid Function Tests
    • Blood Glucose Tests
  • Hematology and Coagulation
    • Complete Blood Count (CBC)
    • Platelet Count and Function Tests
    • Prothrombin Time/International Normalized Ratio
    • Activated Partial Thromboplastin Time (aPTT)
  • Immunoassay and Serology
    • Infectious Disease Testing (HIV, Hepatitis, COVID-19, STIs)
    • Autoimmune Disease Testing
    • Allergy Testing
    • Cancer Biomarker Tests
    • Hormone Level Testing
  • Molecular Blood Tests
    • Nucleic Acid Testing (NAT) for Infectious Diseases
    • Pharmacogenomics
    • Oncology (Liquid Biopsy)
  • Microbiology
  • Blood Culture Tests
  • Gram Stains
  • Others
• Technology Insights (Revenue, USD Bn, 2020 - 2032)
  • Immunoassay
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Microarray
  • Clinical Chemistry Analysis
  • Hematology Analyzers
  • Mass Spectrometry
  • Flow Cytometry
• Product Insights (Revenue, USD Bn, 2020 - 2032)
  • Reagents and Kits
  • Instruments and Analyzers
  • Consumables (tubes, slides, etc.)
  • Software and Services
• Application Insights (Revenue, USD Bn, 2020 - 2032)
  • Disease Diagnosis
  • Wellness and Health Monitoring
  • Therapeutic Drug Monitoring
  • Pre-Natal Screening
  • Pre-Operative Testing
  • Drug of Abuse Testing
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Diagnostic Laboratories
  • Blood Banks
  • Research Institutes and Academia
  • Home Care and Self-Testing Users
• Sample Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Whole Blood
  • Serum
  • Plasma
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Abbott Laboratories
  • Hoffmann-La Roche Ltd
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
  • Beckman Coulter Inc. (Danaher Corporation)
  • Bio-Rad Laboratories Inc.
  • Becton Dickinson and Company (BD)
  • Ortho Clinical Diagnostics
  • Quest Diagnostics Incorporated
  • PerkinElmer Inc.
  • Grifols S.A.
  • bioMerieux SA
  • Cepheid (Danaher Corporation)
  • DiaSorin S.p.A.
  • Nova Biomedical

Sources

Primary Research Interviews

• Industry Stakeholders list
  • Laboratory Directors of National Reference Labs
  • R&D Heads of Diagnostic Technology Companies
• End Users List
  • Clinicians from Multispecialty Hospitals
  • Public Health Program Managers

Government and International Databases

• World Health Organization (WHO)
• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Centers for Disease Control and Prevention (CDC)
• National Institutes of Health (NIH)
• Organization for Economic Co-operation and Development (OECD)

Trade Publications

• Clinical Laboratory News
• The Pathologist
• Diagnostics World
• Laboratory Equipment Magazine
• Medical Laboratory Observer
• Nature Reviews Diagnostics

Academic Journals

• Journal of Clinical Laboratory Analysis
• Clinical Chemistry
• Journal of Molecular Diagnostics
• Blood Advances
• American Journal of Hematology
• Nature Medicine

Reputable Newspapers

• The New York Times – Health Section
• The Guardian – Healthcare Section
• The Washington Post – Health & Science
• Financial Times – Healthcare & Life Sciences
• The Hindu – Health
• The Times of India – Health

Industry Associations

• American Association for Clinical Chemistry (AACC)
• International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
• European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
• World Federation of Hemophilia (WFH)
• International Society of Blood Transfusion (ISBT)
• Association for Diagnostics & Laboratory Medicine (ADLM)

Public Domain Resources

• National Library of Medicine (NLM)
• World Bank Health Data
• European Commission Public Health Portal
• India Ministry of Health and Family Welfare Data Portal
• Global Health Data Exchange (GHDx)

Proprietary Elements

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years